Novavax Inc
Change company Symbol lookup
Select an option...
NVAX Novavax Inc
MRK Merck & Co Inc
HYT BlackRock Corporate High Yield Fund, Inc
FNMA Federal National Mortgage Association
CPKF Chesapeake Financial Shares Inc
AGNC Agnc Investment Corp
BYND Beyond Meat Inc
NDENF Central African Gold Inc
HD Home Depot Inc
ACPS AC Partners Inc
Go

Health Care : Biotechnology | Mid Cap Value
Company profile

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Closing Price
$102.05
Day's Change
-4.99 (-4.66%)
Bid
--
Ask
--
B/A Size
--
Day's High
108.20
Day's Low
100.37
Volume
(Average)
Volume:
2,708,264

10-day average volume:
2,557,587
2,708,264

AMD's stock sinks, Xilinx soars after WSJ report of advanced merger talks

6:37 am ET October 9, 2020 (MarketWatch)
Print

Shares of Advanced Micro Devices Inc. (AMD) sank 5.2% in premarket trading Friday, while Xilinx Inc. (XLNX) soared 17%, after The Wall Street Journal reported that the AMD was in advanced talks to buy rival chip maker Xilinx (http://www.marketwatch.com/story/amd-nearing-potential-30-billion-deal-to-buy-rival-chip-maker-xilinx-11602220913) in a deal valued at more than $30 billion. Xilinx stock was on track to open at the highest level seen during regular-session hours since July 2019. At Thursday's close, the company had a market capitalization of $25.89 billion, while AMD's market cap was $101.57 billion. The WSJ report (https://www.wsj.com/articles/amd-is-in-advanced-talks-to-buy-xilinx-11602205553?mod=searchresults&page=1&pos=2) doesn't indicate whether the deal will be in cash, stock or both. AMD's stock has soared 88.6% year to date through Thursday, while Xilinx shares have gained 8.4%. In comparison, the PHLX Semiconductor Index has rallied 27.4% and the S&P 500 has advanced 6.7%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 09, 2020 06:37 ET (10:37 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.